GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Cyclically Adjusted Book per Share

Vaxart (STU:NB11) Cyclically Adjusted Book per Share : €7.42 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Vaxart Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vaxart's adjusted book value per share for the three months ended in Mar. 2024 was €0.290. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7.42 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Vaxart's average Cyclically Adjusted Book Growth Rate was -27.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -29.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -30.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -26.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vaxart was 14.90% per year. The lowest was -32.70% per year. And the median was 0.40% per year.

As of today (2024-06-22), Vaxart's current stock price is €0.6325. Vaxart's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €7.42. Vaxart's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vaxart was 0.51. The lowest was 0.01. And the median was 0.17.


Vaxart Cyclically Adjusted Book per Share Historical Data

The historical data trend for Vaxart's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Cyclically Adjusted Book per Share Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.18 21.51 14.15 11.33 8.01

Vaxart Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.32 9.76 9.18 8.01 7.42

Competitive Comparison of Vaxart's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PB Ratio falls into.



Vaxart Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vaxart's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.29/131.7762*131.7762
=0.290

Current CPI (Mar. 2024) = 131.7762.

Vaxart Quarterly Data

Book Value per Share CPI Adj_Book
201406 20.043 100.560 26.265
201409 18.944 100.428 24.857
201412 20.942 99.070 27.856
201503 23.584 99.621 31.196
201506 17.643 100.684 23.091
201509 16.108 100.392 21.144
201512 15.028 99.792 19.845
201603 13.472 100.470 17.670
201606 11.705 101.688 15.168
201609 9.284 101.861 12.011
201612 7.556 101.863 9.775
201703 6.440 102.862 8.250
201706 4.737 103.349 6.040
201709 3.319 104.136 4.200
201712 2.597 104.011 3.290
201803 3.533 105.290 4.422
201806 2.679 106.317 3.321
201809 1.919 106.507 2.374
201812 1.383 105.998 1.719
201903 1.334 107.251 1.639
201906 0.888 108.070 1.083
201909 0.371 108.329 0.451
201912 0.242 108.420 0.294
202003 0.393 108.902 0.476
202006 0.372 108.767 0.451
202009 1.021 109.815 1.225
202012 0.920 109.897 1.103
202103 1.255 111.754 1.480
202106 1.350 114.631 1.552
202109 1.390 115.734 1.583
202112 1.321 117.630 1.480
202203 1.200 121.301 1.304
202206 1.071 125.017 1.129
202209 0.963 125.227 1.013
202212 0.778 125.222 0.819
202303 0.618 127.348 0.639
202306 0.517 128.729 0.529
202309 0.441 129.860 0.448
202312 0.345 129.419 0.351
202403 0.290 131.776 0.290

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Vaxart  (STU:NB11) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vaxart's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.6325/7.42
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vaxart was 0.51. The lowest was 0.01. And the median was 0.17.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vaxart Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Vaxart's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (STU:NB11) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines